Allogeneic Haemopoietic Stem Cell Transplantation for Multiple Myeloma or Plasma Cell Leukaemia Using Fractionated Total Body Radiation and High-dose Melphalan Conditioning

By Russell Nigel   Bessell Eric   Stainer Claire   Haynes Andrew   Das-Gupta Emma   Byrne Jenny  

Acta Oncologica, Vol. 39, Iss. 7, 2000-11 ,pp. : 837-841

Informa Healthcare

Access to resources Recommend Favorite

Bortezomib with high dose melphalan conditioning for autologous transplant is safe and effective in patients with heavily pretreated and high risk multiple myeloma

By Wong Doo Nicole  

Leukemia and Lymphoma, Vol. 54, Iss. 7, 2013-07 ,pp. : 1465-1472

Informa Healthcare

Access to resources Recommend Favorite

High-Dose Topotecan, Melphalan, and Cyclophosphamide (TMC) with Stem Cell Support: A New Regimen for the Treatment of Advanced Ovarian Cancer

By Donato M.L.   Gershenson D.M.   Wharton J.T.   Ippoliti C.M.   Aleman A.S.   Bodurka-Bevers D.   Bevers M.W.   Burke T.W.   Levenback C.F.   Wolf J.K.   Freedman R.S.   Bast R.C.   Gajewski J.L.   Champlin R.E.  

Gynecologic Oncology, Vol. 82, Iss. 3, 2001-09 ,pp. : 420-426

Elsevier

Access to resources Recommend Favorite

National Institutes of Health classification for chronic graft-versus-host disease predicts outcome of allo-hematopoietic stem cell transplant after fludarabine–busulfan–antithymocyte globulin conditioning regimen

By Saillard Colombe   Crocchiolo Roberto   Furst Sabine   El-Cheikh Jean   Castagna Luca   Signori Alessio   Oudin Claire   Faucher Catherine   Lemarie Claude   Chabannon Christian   Granata Angela   Blaise Didier  

Leukemia and Lymphoma, Vol. 55, Iss. 5, 2014-05 ,pp. : 1106-1112

Informa Healthcare

Access to resources Recommend Favorite

Therapeutic effects of autologous hematopoietic stem cell transplantation in multiple myeloma patients

By                    

Experimental and Therapeutic Medicine, Vol. 6, Iss. 4, 2013-01 ,pp. : 977-982

Spandidos Publications

Access to resources Recommend Favorite